Last reviewed · How we verify
Vehicle to Oxymetazoline HCL Cream
Vehicle to Oxymetazoline HCL Cream is a Alpha-1 adrenergic agonist Small molecule drug developed by Allergan. It is currently in Phase 3 development for Persistent facial erythema associated with rosacea.
Oxymetazoline HCL is a selective alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and erythema.
Oxymetazoline HCL is a selective alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and erythema. Used for Persistent facial erythema associated with rosacea.
At a glance
| Generic name | Vehicle to Oxymetazoline HCL Cream |
|---|---|
| Sponsor | Allergan |
| Drug class | Alpha-1 adrenergic agonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Oxymetazoline works by stimulating alpha-1 adrenergic receptors on vascular smooth muscle cells, causing vasoconstriction of small blood vessels in the dermis. This reduces blood flow to the affected areas and decreases the appearance of facial erythema and redness. The effect is topical and localized to the area of application.
Approved indications
- Persistent facial erythema associated with rosacea
Common side effects
- Application site erythema
- Application site irritation
- Skin irritation
- Rebound erythema
Key clinical trials
- A Study Comparing Oxymetazoline 1% Cream to RHOFADE (PHASE1)
- A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" (PHASE3)
- Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle to Oxymetazoline HCL Cream CI brief — competitive landscape report
- Vehicle to Oxymetazoline HCL Cream updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Vehicle to Oxymetazoline HCL Cream
What is Vehicle to Oxymetazoline HCL Cream?
How does Vehicle to Oxymetazoline HCL Cream work?
What is Vehicle to Oxymetazoline HCL Cream used for?
Who makes Vehicle to Oxymetazoline HCL Cream?
What drug class is Vehicle to Oxymetazoline HCL Cream in?
What development phase is Vehicle to Oxymetazoline HCL Cream in?
What are the side effects of Vehicle to Oxymetazoline HCL Cream?
What does Vehicle to Oxymetazoline HCL Cream target?
Related
- Drug class: All Alpha-1 adrenergic agonist drugs
- Target: All drugs targeting Alpha-1 adrenergic receptor
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Persistent facial erythema associated with rosacea